Center of Excellence of the European Union
 
Set page width to 800
Login
 
Recent publications

Articles

1.   Telbisz Á, Özvegy-Laczka C, Hegedűs T, Váradi A and Sarkadi B (2013) [23205634]
  Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein.
  Biochem J 450, 387-95
2.   Kasza I, Várady G, Andrikovics H, Koszarska M, Tordai A, Scheffer GL, Németh A, Szakács G and Sarkadi B (2012) [23166586]
  Expression Levels of the ABCG2 Multidrug Transporter in Human Erythrocytes Correspond to Pharmacologically Relevant Genetic Variations.
  PLoS ONE 7, e48423
3.   Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K, Ozvegy-Laczka C, Kéri G, Orfi L, Szakács G, Settleman J, Váradi A and Sarkadi B (2012) [22548830]
  Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
  Biochem Pharmacol 84, 260-7
4.   de Boussac H, Orbán TI, Várady G, Tihanyi B, Bacquet C, Brózik A, Váradi A, Sarkadi B and Arányi T (2012) [22922104]
  Stimulus-induced expression of the ABCG2 multidrug transporter in HepG2 hepatocarcinoma model cells involves the ERK1/2 cascade and alternative promoters.
  Biochem Bioph Res Co 426, 172-6
5.   Brózik A, Hegedüs C, Erdei Z, Hegedus T, Özvegy-Laczka C, Szakács G and Sarkadi B (2011) [21410427]
  Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
  Expert Opin Drug Met 7, 623-42
6.   Sarkadi B and Szakács G (2010) [21031004]
  Understanding transport through pharmacological barriers - are we there yet?
  Nat Rev Drug Discov 9, 897-8